Overexpression of programed death-ligand 1 (PD-L1) in tumor cells is correlated with poor prognosis, and immunotherapies with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies have shown promising results in a variety of cancers (63, 64). The gene discussed is CD274; the disease is cancer.